Risk Minimisation Materials

Fabrazyme (agalsidase beta) - Home Infusion HCP Manual - Risk Minimisation Information for Healthcare Professionals

The objective of this document is to provide guidance to healthcare professionals for the management of patients receiving Fabrazyme (agalsidase beta) at home. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

For Healthcare Professionals

Fabrazyme (agalsidase beta) - Home Infusion Patient Manual - Risk Minimisation Information for Patients

The objective of this document is to provide patients with guidance on how to receive Fabrazyme (agalsidase beta) at home. It is the responsibility of the treating physician to supply this material to patients only if the treating physician decides that the patient is eligible for home infusion treatment. For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

For Healthcare Professionals

Fabrazyme (agalsidase beta)Home Infusion Patient Logbook- Risk Minimisation Information for Patients

For hard copies of this information please contact medical information department on 0800 035 2525 or email [email protected]

Febuxostat DHPC - Increased risk of cardiovascular and all-cause mortality

DHPC describing the increased risk of cardiovascular death and all-cause mortality in patients treated with febuxostat in the CARES study.

CHCs - Checklist for Prescribers

Combined Hormonal Contraceptives - checklist for prescribers

For Healthcare Professionals

CHCs - Q&A on Important Info for Women

Combined hormonal contraceptives: Q&As about the important information for women.

CHCs - Risk of Blood Clots with CHCs

Important Information for women about risk of blood clots with combined hormonal contraceptives.

CHCs - Checklist for Prescribers

Combined Hormonal Contraceptives - checklist for prescribers

For Healthcare Professionals

CHCs - Q&A on Important Info for Women

Combined hormonal contraceptives: Q&As about the important information for women.

CHCs - Risk of Blood Clots with CHCs

Important Information for women about risk of blood clots with combined hormonal contraceptives.

CHCs - Checklist for Prescribers

Combined Hormonal Contraceptives - checklist for prescribers

For Healthcare Professionals

CHCs - Q&A on Important Info for Women

Combined hormonal contraceptives: Q&As about the important information for women.

CHCs - Risk of Blood Clots with CHCs

Important Information for women about risk of blood clots with combined hormonal contraceptives.

Flixabi Healthcare Professional Brochure

IMPORTANT INFORMATION FOR HCPs ON SAFETY AND RISK MINIMISATION FOR INFLIXIMAB

For Healthcare Professionals

Flixabi Patient Alert Card

This Alert Card contains important safety information that patients need to be aware of before and during treatment with Flixabi.

Flixabi Screening Sheet

This screening sheet is intended for use by HCPs who are assessing patients being considered for infliximab therapy.

For Healthcare Professionals

Forxiga (dapagliflozin) – Guide for Healthcare Professionals

For Healthcare Professionals

Forxiga (dapagliflozin) – Guide for Healthcare Professionals

Forxiga (dapagliflozin) – Guide for Healthcare Professionals

For Healthcare Professionals

Forxiga (dapagliflozin) – Patient and carer Guide

For people with type 1 diabetes mellitus and their carers to minimise the risk of Diabetic Ketoacidosis (DKA)

Forxiga (dapagliflozin) – Patient and carer Guide

Forxiga (dapagliflozin) – Patient and carer Guide

Healthcare Professional Guide

Guide for Healthcare Professionals to minimise the risk of Diabetic Ketoacidosis (DKA)

For Healthcare Professionals

Patient Alert Card

Patient Alert Card

Patient Alert Card

Patient Alert Card

Patient and Carer Guide

For people with type 1 diabetes mellitus and their carers to minimise the risk of Diabetic Ketoacidosis (DKA)